Reward processing abnormalities in Parkinson's disease

Movement Disorders

Volumn 26, Issue 8, 2011, Pages 1451-1457

  Kapogiannis, Dimitrios ^a,b   Mooshagian, Eric ^a,c   Campion, Paul ^a   Grafman, Jordan ^a   Zimmermann, Trelawny J ^a   Ladt, Kelsey C ^a   Wassermann, Eric M ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Dopamine; Gambling; Motor cortex; Transcranial magnetic stimulation

Indexed keywords

AMANTADINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE; ENTACAPONE; ESCITALOPRAM; ESTROGEN; LEVODOPA; PAROXETINE; PRAMIPEXOLE; RASAGILINE; SELEGILINE;

AGED; AMPLITUDE MODULATION; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; ENDOPHENOTYPE; EXPECTATION; FEMALE; HIGH RISK BEHAVIOR; HUMAN; INHIBITION (PSYCHOLOGY); MALE; MOTOR CORTEX; NERVOUS SYSTEM PARAMETERS; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; REWARD PROCESSING; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TASK PERFORMANCE; TRANSCRANIAL MAGNETIC STIMULATION;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; COGNITION DISORDERS; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; FEMALE; GAMES, EXPERIMENTAL; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; REWARD; RISK-TAKING; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 79960592810     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23701     Document Type: Article

References (40)

1. Torta DM, Castelli L. Reward pathways in Parkinson's disease: clinical and theoretical implications. Psychiatry Clin Neurosci. 2008; 62: 203-213.
2. Frank MJ, Seeberger LC, O'Reilly R C. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science. 2004; 306: 1940-1943.
3. Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006; 67: 1258-1261.
4. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006; 63: 969-973.
5. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord. 2000; 15: 869-872.
6. Morgan JC, Iyer SS, Sethi KD. Impulse control disorders and dopaminergic drugs. Arch Neurol. 2006; 63: 298-299; author reply 299.
7. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol. 2007; 64: 1089-1096.
8. Schott BH, Niehaus L, Wittmann BC, et al. Ageing and early-stage Parkinson's disease affect separable neural mechanisms of mesolimbic reward processing. Brain. 2007; 130: 2412-2424.
9. Shohamy D, Myers CE, Grossman S, Sage J, Gluck MA. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease. Behav Brain Res. 2005; 156: 191-199.
10. Ziemann U, Rothwell JC, Ridding MC. Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol (Lond). 1996; 496: 873-881.
11. Berardelli A, Inghilleri M, Priori A, et al. Inhibitory cortical phenomena studied with the technique of transcranial stimulation. Electroencephalogr Clin Neurophysiol Suppl. 1996; 46: 343-349.
12. Wassermann EM, Epstein CM, Ziemann U. The Oxford Handbook of Transcranial Stimulation. Oxford, UK, New York: Oxford University Press; 2007.
13. Ziemann U, Tergau F, Bruns D, Baudewig J, Paulus W. Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. Electroencephalogr Clin Neurophysiol. 1997; 105: 430-437.
14. Di Lazzaro V, Oliviero A, Meglio M, et al. Direct demonstration of the effect of lorazepam on the excitability of the human motor cortex. Clin Neurophysiol. 2000; 111: 794-799.
15. Ziemann U, Lonnecker S, Steinhoff BJ, Paulus W. The effect of lorazepam on the motor cortical excitability in man. Exp Brain Res. 1996; 109: 127-135.
16. Gao WJ, Wang Y, Goldman-Rakic PS. Dopamine modulation of perisomatic and peridendritic inhibition in prefrontal cortex. J Neurosci. 2003; 23: 1622-1630.
17. Awenowicz PW, Porter LL. Local application of dopamine inhibits pyramidal tract neuron activity in the rodent motor cortex. J Neurophysiol. 2002; 88: 3439-3451.
18. Godbout R, Mantz J, Pirot S, Glowinski J, Thierry AM. Inhibitory influence of the mesocortical dopaminergic neurons on their target cells: electrophysiological and pharmacological characterization. J Pharmacol Exp Ther. 1991; 258: 728-738.
19. Huda K, Salunga TL, Matsunami K. Dopaminergic inhibition of excitatory inputs onto pyramidal tract neurons in cat motor cortex. Neurosci Lett. 2001; 307: 175-178.
20. Kapogiannis D, Campion P, Grafman J, Wassermann EM. Reward-related activity in the human motor cortex. Eur J Neurosci. 2008; 27: 1836-1842.
21. Bechara A, Damasio H, Tranel D, Damasio AR. The Iowa Gambling Task and the somatic marker hypothesis: some questions and answers. Trends Cogn Sci. 2005; 9: 159-162; discussion 162-154.
22. Damasio AR. The somatic marker hypothesis and the possible functions of the prefrontal cortex. Philos Trans R Soc Lond B Biol Sci. 1996; 351: 1413-1420.
23. Ziemann U, Chen R, Cohen LG, Hallett M. Dextromethorphan decreases the excitability of the human motor cortex. Neurology. 1998; 51( 5): 1320-1324.
24. MacKinnon CD, Gilley EA, Weis-McNulty A, Simuni T. Pathways mediating abnormal intracortical inhibition in Parkinson's disease. Ann Neurol. 2005; 58: 516-524.
25. Gaspar P, Stepniewska I, Kaas JH. Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys. J Comp Neurol. 1992; 325: 1-21.
26. Williams SM, Goldman-Rakic PS. Characterization of the dopaminergic innervation of the primate frontal cortex using a dopamine-specific antibody. Cereb Cortex. 1993; 3: 199-222.
27. Gaspar P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann Neurol. 1991; 30: 365-374.
28. Doyon J. Motor sequence learning and movement disorders. Curr Opin Neurol. 2008; 21: 478-483.
29. de La Fuente-Fernandez R, Lim AS, Sossi V, et al. Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. J Cereb Blood Flow Metab. 2001; 21: 1151-1159.
30. Chen YC, Choi JK, Andersen SL, Rosen BR, Jenkins BG. Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging. Psychopharmacology (Berl). 2005; 180: 705-715.
31. Pizzagalli DA, Evins AE, Schetter EC, et al. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology (Berl). 2008; 196: 221-232.
32. Schmitz Y, Benoit-Marand M, Gonon F, Sulzer D. Presynaptic regulation of dopaminergic neurotransmission. J Neurochem. 2003; 87: 273-289.
33. Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers. Psychopharmacology (Berl). 2006; 187: 498-510.
34. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol. 1996; 312: 35-44.
35. Tobler PN, Fiorillo CD, Schultz W. Adaptive coding of reward value by dopamine neurons. Science. 2005; 307: 1642-1645.
36. Makoff AJ, Graham JM, Arranz MJ, et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics. 2000; 10: 43-48.
37. Wassermann EM, Greenberg BD, Nguyen MB, Murphy DL. Motor cortex excitability correlates with an anxiety-related personality trait. Biol Psychiatry. 2001; 50: 377-382.
38. Gilbert DL, Bansal AS, Sethuraman G, et al. Association of cortical disinhibition with tic, ADHD, and OCD severity in Tourette syndrome. Mov Disord. 2004; 19: 416-425.
39. Gilbert DL, Sallee FR, Zhang J, Lipps TD, Wassermann EM. Transcranial magnetic stimulation-evoked cortical inhibition: a consistent marker of attention-deficit/hyperactivity disorder scores in Tourette syndrome. Biol Psychiatry. 2005; 57: 1597-1600.
40. Gilbert DL, Wang Z, Sallee FR, et al. Dopamine transporter genotype influences the physiological response to medication in ADHD. Brain. 2006; 129: 2038-2046.